Minmin Qin PhD

Dr. Qin has over 20 years of experience in successful development and commercialization of biopharmaceuticals. He specializes in various expression technologies for antibodies and complex glycoproteins, as well as in process development and cGMP manufacturing. In addition to his extensive regulatory filing and senior management experience, Dr. Qin is also a distinguished scholar and has had numerous publications in Nature, Science, Science Translational Medicine, PNAS etc. He is also a co-author of 10 patents.
Dr. Qin was a founding member of BioMarin where he served at his last position as Senior Director of Process Sciences from 1997 to 2004. From 2005 to 2012, he was Senior Director of Process Development at Five Prime Therapeutics. From 2012 to 2017, Dr. Qin served as CTO/SVP of Shanghai JMT-Bio and Zhejiang Teruisi, and Director/CSO of Technology Center for Antibody Therapeutics in National Translational Medicine Center for Molecular Medicine (Xi'an) and Distinguished Professor at Fourth Military Medical University and Xi'an Jiaotong University. Prior to joining us, Dr. Qin was Vice President of Technology and Process Development at WuXi Biologics. Dr. Qin graduated from University of Wisconsin-Madison with Ph.D. in Genetics/Molecular Biology in 1991 and carried out his postdoctoral research at University of California at Berkeley.